FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barron s Online · 5 days ago
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 231.69Add to watchlist-2.15 (-0.92%)At close: Fri. Jun 14, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open232.56High233.71Low230.26
- Mkt Cap33.73BP/E (TTM)29.00Div & YieldN/A & N/A
- Prev. Close233.8452 Wk. Low189.4452 Wk. High298.73
What analysts are sayingTop storiesRelated stocks
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Apr 25, 2023 · The Food and Drug Administration on Tuesday authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the treatment’s effectiveness.
Sep 29, 2023 · TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States. FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA.
